// App-Quantinova.ai

BSH19‐PO‐012 : A single centre experience with azacitidine for MDS, AML and CMML in relation to cytogenetic risk and performance status. Our results suggest azacitidine use in the real world does not replicate AZA‐001 overall survival rates and has poorer outcomes

Researchers

Presenter

  • C. Page

Principal Investigators

  • I. Whalley

  • A. Dann

Medical Centers

  • Hematology

  • Oncology Pharmacy, Ipswich NHS Trust, Ipswich, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

  • Oncology (ONC)

Disease

  • Myelodysplastic Syndrome

  • Acute myelocytic leukemia

  • Lung Cancer

  • Solid malignancies

  • Sepsis

  • Chronic myelomonocytic leukemia

Biomarkers

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Vidaza

Outcome

  • N/A

Study Design

  • Cohort

  • Single Center

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved